Vision RT reins in £250,000 for US push:
This article was originally published in Clinica
London, UK-based 3D imaging specialist Vision RT has secured £250,000 ($504,000) in financing from new investor The Capital Fund in a bid to support its operations in the US. "We have recently appointed a director of sales, North America, who is establishing a direct sales and marketing presence for us in the US," company founder and CEO Dr Norman Smith told Clinica. The investment, which is part of a larger financing round, will also be used to further develop the company's patent-pending technology, the GateCT and GateRT 3D tracking platforms.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.